Raffaella Maria Gadaleta

Author

Also Known As

R Gadaleta, R. Gadaleta, R.M. Gadaleta, Raffaella Gadaleta, Raffaella M Gadaleta, Raffaella M. Gadaleta, Raffaella Maria Gadaleta

Publications

3.1K

Citations

H-Index

Concepts

All Affiliations

University of Bari Aldo Moro Istituto Nazionale Biostrutture e Biosistemi University Medical Center Utrecht Mario Negri Sud Foundation Imperial College London

About

Raffaella Maria Gadaleta is an author at University of Bari Aldo Moro specializing in medicine, gastroenterology, and gastrointestinal pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	483
2	Health Sciences	1	1	64
3	Natural Sciences	1	1	60
4	Public Health	1	1	27
5	Allergy	1	1	63

Raffaella Maria Gadaleta

Publications

1.8K

Citations

H-Index

Page 1

	Year	Citations
Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease Raffaella Maria Gadaleta, Karel J. van Erpecum, Bas Oldenburg, Gut	2011	827
Activation of bile salt nuclear receptor FXR is repressed by pro-inflammatory cytokines activating NF-κB signaling in the intestine Raffaella Maria Gadaleta, Bas Oldenburg, Ellen C.L. Willemsen, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease InflammationCytokineSignal TransductionBiliary TractGastrointestinal Pharmacology	2011	181
Farnesoid X Receptor (FXR) Activation and FXR Genetic Variation in Inflammatory Bowel Disease Rian M. Nijmeijer, Raffaella Maria Gadaleta, Saskia W. C. van Mil, PLoS ONE	2011	113
Fibroblast Growth Factor 19 modulates intestinal microbiota and inflammation in presence of Farnesoid X Receptor Raffaella Maria Gadaleta, Oihane García‐Irigoyen, Marica Cariello, EBioMedicine	2020	109
Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer Luca Magnani, Gianmaria Frigè, Raffaella Maria Gadaleta, Nature Genetics Breast OncologyMedicineAromatase Inhibitor ResistanceCancer BiologyAromatase	2017	88
Low HDL-cholesterol levels predict hepatocellular carcinoma development in individuals with liver fibrosis Lucilla Crudele, Carlo De Matteis, Elena Piccinin, JHEP Reports Liver FibrosisHepatologyMedicineLiver PhysiologyLow Hdl-cholesterol Levels	2022	64
Extra-Virgin Olive Oil from Apulian Cultivars and Intestinal Inflammation Marica Cariello, Annalisa Contursi, Raffaella Maria Gadaleta, Nutrients Chronic Inflammatory DiseasesGastrointestinal PharmacologyImmunologyGastroenterologyPolyphenolics	2020	63
Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders Roberto Pellicciari, Daniela Passeri, Francesca Franco, Journal of Medicinal Chemistry Gastrointestinal PharmacologyGastroenterologyPathology3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic AcidCholangiopathies	2016	60
Uncoupling FoxO3A mitochondrial and nuclear functions in cancer cells undergoing metabolic stress and chemotherapy Valentina Celestini, Tuğsan Tezil, Luciana Russo, Cell Death and Disease	2018	53
Suppression of Hepatic Bile Acid Synthesis by a non-tumorigenic FGF19 analogue Protects Mice from Fibrosis and Hepatocarcinogenesis Raffaella Maria Gadaleta, Natasha Scialpi, Cláudia Maria Peres, Scientific Reports	2018	52

Page 1